High-Tech Foundation Fund invests in Lophius Biosciences
Lophius Biosciences GmbH is a spin off from the Institute for Medical Microbiology and Hygiene and of the Clinic and Policlinic for Internal Medicine of the University Clinic in Regensburg. The young biotech company offers services for quality control and the evaluation of the efficacy and safety of biologically active substances. Furthermore Lophius Biosciences develop novel products for the diagnosis of acute infectious diseases and autoimmune disease. For the rapid and efficient identification of disease specific target structures, the company is building up a technology platform (“Epitop-Databank”). The company has now successfully sealed its first finance round. The High-Tech Foundation Fund and Bayern Kapital are investing together 600,000 Euro in the young company. The capital should facilitate the development of diagnosis kits for early detection of diseases carrying high risk such as tuberculosis, which is currently on the rise again. Also novel diagnosis of autoimmune disease already in its earlier stages (e. g. multiple sclerosis, type1 diabetes, rheumatoid arthritis) is now for the first time ever closer within grasp with the process now patented.
For more information see: